Clinical TrialMay 21, 2026, 05:07 PM
Eikon Therapeutics to Present Clinical Data at ASCO Meeting
AI Summary
Eikon Therapeutics announced the publication of full-text abstracts for its lead clinical programs, EIK1001, EIK1003, and EIK1005, which will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The six accepted presentations will highlight updated clinical progress across the company's oncology pipeline, evaluating both monotherapy and combination strategies in patients with advanced diseases.
Key Highlights
- Eikon to present six abstracts at the 2026 ASCO Annual Meeting starting May 29.
- Presentations include updated data for TLR7/8 dual-agonist EIK1001.
- EIK1001 trials cover non-small cell lung cancer (NSCLC) and advanced melanoma.
- Updated data for PARP1 inhibitor EIK1003 in advanced solid tumors.
- EIK1003 is being evaluated for breast, ovarian, prostate, or pancreatic cancer.
- Early development progress for WRN inhibitor EIK1005.
- EIK1005 is for tumors with DNA replication abnormalities and advanced solid tumors.
Price Impact
More from EIKN